m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00401)
Target Name Suppressor of cytokine signaling 2 (SOCS2)
Synonyms
SOCS-2; Cytokine-inducible SH2 protein 2; CIS-2; STAT-induced STAT inhibitor 2; SSI-2; CIS2; SSI2; STATI2
    Click to Show/Hide
Gene Name SOCS2
Chromosomal Location 12q
Function
SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS2 appears to be a negative regulator in the growth hormone/IGF1 signaling pathway. Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
    Click to Show/Hide
Gene ID 8835
Uniprot ID
SOCS2_HUMAN
HGNC ID
HGNC:19382
Ensembl Gene ID
ENSG00000120833
KEGG ID
hsa:8835
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SOCS2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 2 (YTHDF2) [READER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF2
Cell Line Human umbilical cord blood CD34+ cells Homo sapiens
Treatment: YTHDF2 knockdown UCB CD34+ cells
Control: Wild type UCB CD34+ cells
 GSE107956
Regulation
logFC: 9.71E-01
p-value: 1.71E-04
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between SOCS2 and the regulator
Cell Line Hela Homo sapiens
Regulation logFC: 1.81E+00 GSE49339
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses Suppressor of cytokine signaling 2 (SOCS2) expression in HCC through an m6A-YTHDF2-dependent mechanism.
Target Regulation Down regulation
Responsed Disease Liver cancer ICD-11: 2C12
 Disease Info 
Cell Process Cells proliferation
Cells migration
Cells invasion
RNA degradation (hsa03018)
In-vitro Model Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
MHCC97-L Adult hepatocellular carcinoma Homo sapiens CVCL_4973
In-vivo Model For the subcutaneous implantation model, 2 × 106 METTL3 stable knockdown Huh-7 cells or METTL3 overexpression MHCC97L cells were injected subcutaneously into BABL/cAnN-nude mice. For orthotopic implantation, wild-type and METTL3 knockout Huh-7 cells were luciferase labelled, and 2 × 106 cells were then injected orthotopically into the left liver lobe of nude mice.
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line ARPE-19 cell line Homo sapiens
Treatment: shMETTL3 ARPE-19 cells
Control: shControl ARPE-19 cells
 GSE202017
Regulation
logFC: 8.91E-01
p-value: 2.94E-04
More Results Click to View More RNA-seq Results
In total 5 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary miR-302a was identified to target METTL3, which could inhibit Suppressor of cytokine signaling 2 (SOCS2) expression via m6A modification in glioma.
Target Regulation Down regulation
Responsed Disease Glioma ICD-11: 2A00.0
 Disease Info 
Pathway Response Transcriptional misregulation in cancer hsa05202
Cell Process RNA stability
In-vitro Model LN-229 Glioblastoma Homo sapiens CVCL_0393
LN-18 Glioblastoma Homo sapiens CVCL_0392
HEB (human normal glial cell line HEB were obtained from Tongpai (Shanghai) biotechnology co., LTD (Shanghai, China))
In-vivo Model Mice were subcutaneously injected with 2.5 × 106 U251 cells stably infected with OE-NC, OE-JMJD1C, OE-NC and sh-NC, OE-JMJD1C and sh-NC or OE-JMJD1C and sh-SOCS2 (n = 10 in each group) in 0.1 ml PBS.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [3]
Response Summary METTL3-KO in gastric cancer cells resulted in the suppression of cell proliferation by inducing Suppressor of cytokine signaling 2 (SOCS2), suggesting a potential role of elevated METTL3 expression in gastric cancer progression.
Target Regulation Down regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
In-vitro Model AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene [4]
Response Summary An increased level of METTL3 may maintain the tumorigenicity of colon cancer cells by suppressing Suppressor of cytokine signaling 2 (SOCS2).
Target Regulation Down regulation
Responsed Disease Colon cancer ICD-11: 2B90
 Disease Info 
Cell Process Cell proliferation
In-vitro Model SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses Suppressor of cytokine signaling 2 (SOCS2) expression in HCC through an m6A-YTHDF2-dependent mechanism.
Target Regulation Down regulation
Responsed Disease Liver cancer ICD-11: 2C12
 Disease Info 
Cell Process Cells proliferation
Cells migration
Cells invasion
RNA degradation (hsa03018)
In-vitro Model Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
MHCC97-L Adult hepatocellular carcinoma Homo sapiens CVCL_4973
In-vivo Model For the subcutaneous implantation model, 2 × 106 METTL3 stable knockdown Huh-7 cells or METTL3 overexpression MHCC97L cells were injected subcutaneously into BABL/cAnN-nude mice. For orthotopic implantation, wild-type and METTL3 knockout Huh-7 cells were luciferase labelled, and 2 × 106 cells were then injected orthotopically into the left liver lobe of nude mice.
Experiment 5 Reporting the m6A Methylation Regulator of This Target Gene [5]
Response Summary METTL3 knock-down experiment revealed that expressions of SOCS family members SOCS1, Suppressor of cytokine signaling 2 (SOCS2), SOCS4, SOCS5, and SOCS6 were increased after METTL3 knock-down. It indicated that METTL3 is involved in the development of Graves' disease (GD) by inducing mRNA m6A methylation modification of SOCS family members.
Target Regulation Down regulation
Responsed Disease Graves disease ICD-11: 5A02.0
 Disease Info 
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
Brain cancer [ICD-11: 2A00]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary miR-302a was identified to target METTL3, which could inhibit Suppressor of cytokine signaling 2 (SOCS2) expression via m6A modification in glioma.
Responsed Disease Glioma [ICD-11: 2A00.0]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Transcriptional misregulation in cancer hsa05202
Cell Process RNA stability
In-vitro Model LN-229 Glioblastoma Homo sapiens CVCL_0393
LN-18 Glioblastoma Homo sapiens CVCL_0392
HEB (human normal glial cell line HEB were obtained from Tongpai (Shanghai) biotechnology co., LTD (Shanghai, China))
In-vivo Model Mice were subcutaneously injected with 2.5 × 106 U251 cells stably infected with OE-NC, OE-JMJD1C, OE-NC and sh-NC, OE-JMJD1C and sh-NC or OE-JMJD1C and sh-SOCS2 (n = 10 in each group) in 0.1 ml PBS.
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response []
Response Summary In this review, we discuss the specific roles of m6A "writers", "erasers", and "readers" in normal physiology and how their altered expression promotes tumorigenesis. We also describe the potential of exploiting the aberrant expression of these enzymes for cancer diagnosis, prognosis, and the development of novel therapies. The abnormal expression of m6A regulatory enzymes affects m6A abundance and consequently dysregulates the expression of tumor suppressor genes and oncogenes, including MYC, Suppressor of cytokine signaling 2 (SOCS2), ADAM19, and PTEN.
Responsed Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Gastric cancer [ICD-11: 2B72]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [3]
Response Summary METTL3-KO in gastric cancer cells resulted in the suppression of cell proliferation by inducing Suppressor of cytokine signaling 2 (SOCS2), suggesting a potential role of elevated METTL3 expression in gastric cancer progression.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
Colon cancer [ICD-11: 2B90]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [4]
Response Summary An increased level of METTL3 may maintain the tumorigenicity of colon cancer cells by suppressing Suppressor of cytokine signaling 2 (SOCS2).
Responsed Disease Colon cancer [ICD-11: 2B90]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Cell Process Cell proliferation
In-vitro Model SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses Suppressor of cytokine signaling 2 (SOCS2) expression in HCC through an m6A-YTHDF2-dependent mechanism.
Responsed Disease Liver cancer [ICD-11: 2C12]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Cell Process Cells proliferation
Cells migration
Cells invasion
RNA degradation (hsa03018)
In-vitro Model Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
MHCC97-L Adult hepatocellular carcinoma Homo sapiens CVCL_4973
In-vivo Model For the subcutaneous implantation model, 2 × 106 METTL3 stable knockdown Huh-7 cells or METTL3 overexpression MHCC97L cells were injected subcutaneously into BABL/cAnN-nude mice. For orthotopic implantation, wild-type and METTL3 knockout Huh-7 cells were luciferase labelled, and 2 × 106 cells were then injected orthotopically into the left liver lobe of nude mice.
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses Suppressor of cytokine signaling 2 (SOCS2) expression in HCC through an m6A-YTHDF2-dependent mechanism.
Responsed Disease Liver cancer [ICD-11: 2C12]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Cell Process Cells proliferation
Cells migration
Cells invasion
RNA degradation (hsa03018)
In-vitro Model Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
MHCC97-L Adult hepatocellular carcinoma Homo sapiens CVCL_4973
In-vivo Model For the subcutaneous implantation model, 2 × 106 METTL3 stable knockdown Huh-7 cells or METTL3 overexpression MHCC97L cells were injected subcutaneously into BABL/cAnN-nude mice. For orthotopic implantation, wild-type and METTL3 knockout Huh-7 cells were luciferase labelled, and 2 × 106 cells were then injected orthotopically into the left liver lobe of nude mice.
Thyrotoxicosis [ICD-11: 5A02]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [5]
Response Summary METTL3 knock-down experiment revealed that expressions of SOCS family members SOCS1, Suppressor of cytokine signaling 2 (SOCS2), SOCS4, SOCS5, and SOCS6 were increased after METTL3 knock-down. It indicated that METTL3 is involved in the development of Graves' disease (GD) by inducing mRNA m6A methylation modification of SOCS family members.
Responsed Disease Graves disease [ICD-11: 5A02.0]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
References
Ref 1 RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018 Jun;67(6):2254-2270. doi: 10.1002/hep.29683. Epub 2018 Apr 19.
Ref 2 Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a. Clin Transl Med. 2021 Sep;11(9):e424. doi: 10.1002/ctm2.424.
Ref 3 Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation. Oncol Lett. 2020 Sep;20(3):2191-2198. doi: 10.3892/ol.2020.11794. Epub 2020 Jul 1.
Ref 4 m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation. Oncol Rep. 2020 Sep;44(3):973-986. doi: 10.3892/or.2020.7665. Epub 2020 Jun 26.
Ref 5 METTL3 Is Involved in the Development of Graves' Disease by Inducing SOCS mRNA m6A Modification. Front Endocrinol (Lausanne). 2021 Sep 20;12:666393. doi: 10.3389/fendo.2021.666393. eCollection 2021.